924 material Form 8-K filings that 737 companies we cover made with the SEC in January 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Lafayette Digital Acquisition Corp. I, a Cayman Islands blank check company, closed its initial public offering on January 12, 2026, selling 28,750,000 units at $10.00 each for gross proceeds of $287.5 million, including the full exercise of the underwriters' over-allotment option. The filing says the net proceeds, including $10,062,500 in deferred underwriting commissions, were placed in a trust account for public shareholders, and the company intends to use the proceeds to pursue a business combination with one or more businesses.
IPO closed January 12, 2026: 28,750,000 units at $10.00 per unit, including 3,750,000 over-allotment units, for gross proceeds of $287,500,000.
Each unit includes one Class A ordinary share and one-fourth of one redeemable warrant exercisable at $11.50 per share.
Private placement of 760,000 units for $7,600,000 to the Sponsor (435,000 units) and BTIG, LLC (325,000 units).
Jason Glazer and Robert Cusack were appointed to the board on January 8, 2026; the amended and restated articles were adopted in connection with the IPO.
Amphastar entered into an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology on January 6, 2026, for AMP-110, a fully synthetic corticotropin compound in early-phase human clinical development, covering the United States and Canada. Hanxin is controlled by family members of Amphastar's CEO and Chairman, so the agreement and two related amendments are related party transactions, and the company says the amendments are not expected to be material.
Amphastar made a $2 million upfront payment to Hanxin, with up to $14 million in development milestones and up to $75 million in sales milestones.
Royalties payable by Amphastar to Hanxin are capped at $7.5 million per calendar year and $60 million in total accumulated.
Dr. Jack Zhang and Dr. Mary Luo and certain family members own a majority of Hanxin; the Audit Committee approved the distribution and manufacturing amendments.
The Distribution and Manufacturing Amendments expand territories; their value is not determinable until sales occur in the expanded regions.
Shake Shack released preliminary unaudited results for the fourth quarter and fiscal 2025, showing total revenue of $400.5 million for the quarter and $1.45 billion for the year, with same-Shack sales up 2.1% and 2.3%. The company said the last six weeks of the quarter did not meet its expectations because of inclement weather, and it issued initial fiscal 2026 guidance of $1.6 billion to $1.7 billion in total revenue and $237.0 million to $245.0 million in adjusted EBITDA. The figures remain subject to audit and the Form 10-K.
4Q25 total revenue of $400.5 million; FY25 total revenue of $1.45 billion
Same-Shack sales up 2.1% in 4Q25 and 2.3% in FY25; last six weeks of 4Q25 missed expectations due to weather
FY26 guidance: net income of $50.0 million to $60.0 million and adjusted EBITDA of $237.0 million to $245.0 million
45 Company-operated Shacks opened in FY25; 55 to 60 planned for 2026
Inspire Medical Systems reported preliminary, unaudited revenue for the fourth quarter and full year 2025, with full-year revenue up about 14% from 2024, and gave initial 2026 revenue guidance of $1,003 million to $1,013 million, a 10% to 11% increase. The company said final results may differ and the audit is not complete. It also named Matthew Osberg as Chief Financial Officer, starting January 19, 2026, succeeding interim CFO Richard Buchholz.
Q4 2025 revenue preliminarily estimated at $268.9 million to $269.1 million, about 12% higher than Q4 2024
Full-year 2025 revenue preliminarily estimated at $911.8 million to $912.0 million, about 14% higher than 2024
2026 revenue guidance of $1,003 million to $1,013 million, reaffirmed from the outlook given on the third-quarter 2025 call; excludes any increase from reimbursement
Matthew Osberg's start date is January 19, 2026; his CFO appointment is effective after the 2025 Form 10-K is filed, with a $650,000 base salary and a $600,000 sign-on bonus
Arrowhead Pharmaceuticals issued $700 million of 0.00% convertible senior notes due January 15, 2032, including $75 million from the underwriters' full exercise of their over-allotment option. The company also spent approximately $47.9 million on capped call transactions, which are expected to reduce potential dilution from future conversions of the notes.
Notes issued January 12, 2026: $700 million principal, 0.00% interest rate, maturing January 15, 2032
Initial conversion price of approximately $87.07 per share; the company may settle conversions in cash, shares or a combination
Capped call transactions cost approximately $47.9 million, with a cap price of approximately $119.33 per share
Company may redeem notes on or after January 16, 2029 if the stock exceeds 130% of the conversion price under specified conditions
Moody's Corporation named Lisa P. Sawicki, former Chair of the Global Board at PricewaterhouseCoopers, as a director effective March 16, 2026, expanding the board to ten members. She will also join the Audit and Governance & Nominating committees.
Election effective March 16, 2026; board grows to ten directors
Annual cash retainer of $120,000, paid quarterly
Annual restricted stock unit award equivalent in value to $230,000, vesting on the first anniversary of grant
Sawicki served as Chair of the Global Board at PwC from 2021 to 2025
EOG Resources filed an 8-K under Item 2.02 that covers its price risk management for the fourth quarter of 2025. The excerpt shows EOG paid a net $21 million to settle financial commodity derivative contracts, and it reports average Q4 2025 benchmark prices. The excerpt does not include revenue, profit, EPS or guidance, so it does not show whether results improved or declined.
Net cash paid for settlements of financial commodity derivative contracts in Q4 2025: $21 million
Q4 2025 NYMEX West Texas Intermediate crude averaged $59.17 per barrel; Henry Hub natural gas averaged $3.55 per million British thermal units
No cash received under the 10-year Brent Linked Gas Sales Contract; deliveries are expected to start in January 2027
BioMarin said at the J.P. Morgan Healthcare Conference that preliminary 2025 total revenue was about $3.2 billion, within its prior guidance, and that VOXZOGO sales were about $920 million. The company also expects a fourth-quarter 2025 Roctavian asset write-down of $230 million to $260 million, which reduces non-GAAP diluted EPS by $0.60 to $0.64 per share, while its non-GAAP EPS guidance excluding the write-down is unchanged.
Preliminary 2025 total revenue of about $3.2 billion, against prior guidance of $3.15 billion to $3.2 billion
VOXZOGO 2025 revenue of about $920 million, against prior guidance of $900 million to $935 million
Roctavian write-down of $230 million to $260 million in Q4 2025, with $120 million to $125 million reducing non-GAAP diluted EPS by $0.60 to $0.64 per share
Full fourth-quarter and 2025 results expected in February 2026; figures are unaudited and preliminary
Quest Diagnostics filed a presentation from its January 12, 2026 appearance at the 44th Annual J.P. Morgan Healthcare Conference, where Chairman, CEO and President Jim Davis discussed strategy and market trends. The filing contains no new quarterly results, but it restates a long-term outlook for revenue, adjusted EPS and capital deployment through 2027.
Long-term outlook beyond 2025: 4% to 5% revenue CAGR and 7% to 9% adjusted EPS CAGR, with operating margins up 75 to 150 basis points by the end of 2027.
Targeted capital deployment for 2025 to 2027 includes $4.5 billion to $5.0 billion in operating cash flow and $3.0 billion to $3.3 billion in free cash flow.
Planned uses include about $1.5 billion for acquisitions, about $1.0 billion for dividends and about $0.7 billion for share repurchases.
The presentation says the capital deployment plan is consistent with what the company shared at its March 2025 Investor Day.
Crown Castle said DISH Wireless defaulted on its payment obligations and that it has terminated its wireless infrastructure agreement with DISH, seeking to recover more than $3.5 billion in remaining payments. The company said it does not expect the termination to affect its full-year 2025 results, but the filing does not describe how the dispute will be resolved or how much cash will be collected.
DISH Wireless defaulted on payment obligations; Crown Castle delivered a notice of default and termination on January 12, 2026.
Crown Castle seeks to recover more than $3.5 billion in remaining payments owed under the agreement.
Crown Castle does not anticipate the termination to affect its full-year 2025 financial results.
T-Mobile USA, a wholly-owned subsidiary of T-Mobile US, closed an underwritten public offering of $1.15 billion of 5.000% senior notes due 2036 and $850 million of 5.850% senior notes due 2056 on January 12, 2026. Net proceeds are expected to refinance existing indebtedness on an ongoing basis or for general corporate purposes, and the notes are guaranteed on a senior unsecured basis by the parent and certain subsidiaries.
2036 Notes: $1.15 billion principal at a 5.000% coupon
2056 Notes: $850 million principal at a 5.850% coupon
Offering closed January 12, 2026, under an underwriting agreement dated January 7, 2026
Proceeds expected for refinancing existing debt or general corporate purposes
Artisan Partners reported preliminary assets under management of $179.9 billion as of December 31, 2025, in a press release filed with the 8-K. The filing also says the board added Clarence Kane Brenan as a director on January 9, 2026, expanding it from eight to nine members, and that a subsidiary closed its acquisition of Grandview Property Partners, LLC on January 2, 2026.
Total firm AUM was $179.9 billion as of December 31, 2025, including $87.8 billion in Artisan Funds and Artisan Global Funds and $92.1 billion in separate accounts and other AUM.
December month-end AUM includes the impact of approximately $640 million of Artisan Funds distributions that were not reinvested.
Clarence Kane Brenan, former CEO of TIFF Investment Management, was appointed to the board on January 9, 2026 and to the Compensation Committee.
A subsidiary closed its previously announced acquisition of 100% of the equity of Grandview Property Partners, LLC on January 2, 2026.
Chipotle said two executives, Chief Legal Officer Roger Theodoredis and President and Chief Brand Officer Chris Brandt, have transitioned out of their executive roles effective January 12, 2026, and will stay on in advisory roles for a limited period. Chief Human Resources Officer Ilene Eskenazi takes on the combined chief legal and human resources role, and Stephanie Perdue is interim Chief Marketing Officer while the company searches for a permanent CMO. The company also reaffirmed its full-year 2025 guidance issued in October, which keeps its prior financial outlook unchanged.
Ilene Eskenazi appointed Chief Legal and Human Resources Officer, effective immediately, succeeding Roger Theodoredis
Stephanie Perdue, Vice President of Brand Marketing, named interim Chief Marketing Officer, succeeding Chris Brandt
Company reaffirmed full-year 2025 financial guidance issued in October 2025
Fourth quarter and fiscal year 2025 earnings call scheduled for February 3, 2026
Crescent Energy said it expects to report about $165 million of total cash received from hedge positions for the full year 2025 and about $84 million for the fourth quarter, based on preliminary figures. The company says the amounts are subject to change and final results will appear in its 2025 Form 10-K.
Full-year 2025 total cash received from hedges: approximately $165 million
Three months ended December 31, 2025 total cash received from hedges: approximately $84 million
Settlements of derivatives acquired in the SilverBow and Vital mergers contributed $83 million for the year and $34 million for the quarter
Final amounts to be reported in the 10-K for the year ended December 31, 2025
Option Care Health said it expects 2025 net revenue of $5.645 billion to $5.655 billion and adjusted diluted EPS of $1.72 to $1.76, both preliminary and unaudited, and gave preliminary 2026 guidance of $5.8 billion to $6.0 billion in net revenue and $1.82 to $1.92 in adjusted diluted EPS. The company also raised its 2025 share repurchase authorization from $500 million to $1 billion, which matters to shareholders because it expands the room for buybacks.
FY2025 preliminary net revenue $5.645 billion to $5.655 billion; adjusted diluted EPS $1.72 to $1.76; GAAP diluted EPS $1.27 to $1.29
FY2026 preliminary guidance: net revenue $5.8 billion to $6.0 billion; adjusted diluted EPS $1.82 to $1.92; adjusted EBITDA $480 million to $505 million
Board approved on January 9, 2026 to raise the 2025 share repurchase authorization from $500 million to $1 billion; $307 million repurchased in full-year 2025
FY2025 cash flow from operations below $320 million; the company says Stelara and Stelara biosimilars will be a 2026 headwind of $25 million to $35 million in gross profit
Regions Financial said Chief Financial Officer David Turner will retire effective March 31, 2026, and Anil Chadha, currently Controller and head of Corporate Finance, will succeed him as Senior Executive Vice President, Chief Financial Officer. A CFO change is a significant leadership transition, and the filing says the two will work together through March to ensure a smooth handoff, while Chadha's compensation terms have not yet been disclosed.
David J. Turner, Jr. retires as CFO effective March 31, 2026, after about 40 years in auditing and finance, including 20 years at the bank
Anil D. Chadha, 47, becomes CFO upon Turner's retirement; he has been Controller since December 2021 and head of Corporate Finance since December 2023
Regions says material compensation terms for both executives will be disclosed once approved
Exelixis said preliminary, unaudited fiscal 2025 net product revenue was about $2.123 billion and total revenue was about $2.320 billion. It also gave fiscal 2026 net product revenue guidance of $2.325 billion to $2.425 billion, which excludes any revenue from a potential zanzalintinib launch. The audit is ongoing, and final results are due February 10, 2026, so the figures could change.
Preliminary fiscal 2025 total revenues of about $2.320 billion and net product revenues of about $2.123 billion
Fiscal 2026 guidance: total revenues of $2.525 billion to $2.625 billion and net product revenues of $2.325 billion to $2.425 billion
Audited fiscal 2025 results are scheduled for release on February 10, 2026
An October 2025 buyback authorizes up to an additional $750 million of stock repurchases before December 31, 2026
NetApp's board increased its size from nine to ten authorized directors and appointed Paul Fipps, President of Global Customer Operations at ServiceNow, to fill the new seat, effective with the January 8, 2026 board action. The company said nine of the ten directors are independent, and Fipps will join the non-employee director compensation program. The filing contains no financial results or guidance, so the appointment is a governance change rather than a change to the company's financial outlook.
Board approved on January 8, 2026 to increase authorized directors from nine to ten and appointed Paul Fipps to fill the vacancy.
Fipps is President of Global Customer Operations at ServiceNow, previously EVP of Worldwide Sales at ServiceNow and President of Under Armour Connected Fitness.
NetApp says nine of its ten directors are independent and 50% were appointed within the last five years.
Fipps will receive compensation under the non-employee director program and is expected to sign the standard indemnification agreement.
On January 12, 2026, Sonos increased its Board from eight to ten members and appointed Carmine Arabia, Mandy Fields and Joe Kennedy as directors, effective immediately. The filing discloses no committee roles, and the Board determined all three are independent under Nasdaq standards, so the change adds board capacity rather than altering management.
Board expanded from eight to ten members; Arabia (Class II, term to 2026 annual meeting), Fields (Class III, to 2027) and Kennedy (Class I, to 2028) appointed effective immediately
No committee appointments made at this time
Each new director is to receive standard non-employee director compensation and a standard indemnification agreement
Arabia is VP of Devices at Meta; Fields is CFO of e.l.f. Beauty; Kennedy is a former Pandora CEO and President
Verizon's Human Resources Committee approved an amendment to a letter agreement with CEO Daniel H. Schulman that sets updated terms for a $30 million target value performance stock unit award. The award, which vests on December 31, 2027 if earned, ties half its value to adjusted earnings per share targets and half to relative total shareholder return.
Committee approved the amendment on January 8, 2026, to the letter agreement with Daniel H. Schulman dated October 13, 2025
Target value of the PSU award is $30 million, to be granted in the first quarter of 2026 on the annual long-term incentive grant date
50% vests on adjusted EPS targets and 50% on relative total shareholder return, with payouts of 0-200% of target for the TSR portion
Award vests, to the extent earned, on December 31, 2027, generally subject to continued employment
ANI Pharmaceuticals said preliminary, unaudited 2025 results are within or above its prior guidance, with Cortrophin Gel net revenues up 76% for the year. It also issued 2026 guidance calling for total net revenues of $1.055 billion to $1.115 billion and adjusted non-GAAP diluted EPS of $8.83 to $9.34, and said the 2025 figures may change materially before the audit is complete.
Preliminary 2025 total net revenues are expected to be within or above $854 million to $873 million, adjusted non-GAAP EBITDA $221 million to $228 million, and adjusted non-GAAP diluted EPS $7.37 to $7.64.
Cortrophin Gel net revenues were approximately $347.8 million for 2025, up 76% year over year, and approximately $111.4 million for the fourth quarter, up 88%.
2026 guidance: total net revenues $1.055 billion to $1.115 billion, adjusted non-GAAP EBITDA $275 million to $290 million, and adjusted non-GAAP diluted EPS $8.83 to $9.34.
The company had approximately $285 million in unrestricted cash and cash equivalents as of December 31, 2025; the company plans to report full 2025 results in late February.
Pool Corporation announced that Kenneth G. St. Romain, Senior Vice President, will retire in 2026 and will stay in his role until later in the year to assist with the transition. The company also said John B. Watwood joined as Executive Vice President effective January 12, 2026, leading North American swimming pool operations and overseeing digital and technology initiatives. The filing contains no financial results, so the change is administrative in nature for shareholders.
Kenneth G. St. Romain, Senior Vice President, will retire in 2026 and has not set a specific retirement date.
John B. Watwood joined as Executive Vice President effective January 12, 2026, reporting to CEO Peter D. Arvan.
Watwood will lead North American swimming pool operations and oversee digital and technology initiatives.
Watwood previously held management roles at Motion Industries, Inc. since 2008, most recently as Senior Vice President of Sales and Operations for the United States and Canada.
Masco entered into an agreement effective January 12, 2026 with former Group President, Decorative Architectural Products Imran Ahmad, whose service ended December 31, 2025. The agreement sets out a $998,875 cash payment plus conditional payments tied to 2025 bonus and 2023-2025 LTIP performance goals, and a 90-day window to exercise vested options and stock appreciation rights.
Cash payment of $998,875 to Imran Ahmad
2025 cash bonus and 2023-2025 LTIP cash payment are conditional on established performance goals being met
Cash equivalent of an annual restricted stock unit award based on his individual target opportunity
Vested stock options and SARs exercisable for 90 days after service ended December 31, 2025
CAVA Group announced that Douglas W. Thompson will become its Chief Operations Officer effective March 2, 2026, overseeing restaurant operations and field teams and reporting to CEO Brett Schulman. The filing sets out his compensation, including a $550,000 base salary, a target cash bonus of 75% of base salary, and a $200,000 relocation and sign-on bonus, which adds a new operations executive and the associated pay terms for shareholders to note.
Thompson, 62, becomes Chief Operations Officer effective March 2, 2026 and reports directly to CEO Brett Schulman.
Offer letter provides a $550,000 annual base salary and a target cash bonus of 75% of base salary.
Equity award with approximate grant date value of $1,200,000 expected from fiscal 2027, plus a one-time restricted stock unit grant of approximately $500,000 and a $200,000 sign-on bonus.
Thompson was CEO of Tumble 22 Texas Chicken Joint from October 2022 and served as COO of Texas Roadhouse from August 2018 to December 2021.
NETSTREIT issued a business update for the fourth quarter and full year 2025 and initiated 2026 adjusted funds from operations (AFFO) per share guidance of $1.35 to $1.39. The company reaffirmed its 2025 AFFO per share guidance of $1.30 to $1.31 and reported record gross investment activity of $657.1 million at a 7.5% blended cash yield for 2025. The update did not include revenue, net income or GAAP earnings per share figures.
2026 AFFO per share guidance: $1.35 to $1.39; 2026 net investment activity expected at $350.0 million to $450.0 million
2025 AFFO per share guidance of $1.30 to $1.31 reaffirmed; 2025 gross investments totaled $657.1 million, a record per the release
Total liquidity of $1,037.4 million as of December 31, 2025; Fitch assigned an investment grade rating of BBB- in December 2025
Guidance includes $0.015 to $0.03 per share of estimated dilution from outstanding forward equity
Tanger's operating partnership issued $250 million of 2.375% exchangeable senior notes due January 15, 2031, including a $30 million option exercise. Net proceeds were about $243 million, which the company plans to use to repay a $350 million 3.125% note maturing September 1, 2026, repay credit line debt, and for general corporate purposes. The notes can be exchanged for Tanger common shares at an initial price of about $41.55, a 22.5% premium over the January 7, 2026 closing price of $33.92.
Notes: $250 million principal at 2.375% interest, maturing January 15, 2031, including $30 million from full exercise of the initial purchasers' option.
Net proceeds of about $243 million; about $20 million used to repurchase roughly 0.6 million common shares at $33.92 and about $9 million used for capped call transactions.
Planned use: repay the $350 million 3.125% senior notes due September 1, 2026, and outstanding unsecured line of credit debt.
Initial exchange price of about $41.55 per share; the notes are guaranteed by Tanger Inc. on a senior unsecured basis.
Alexandria Real Estate amended the 2025 long-term incentive grant for Executive Chairman Joel S. Marcus, so 100% of the grant now vests only on corporate performance criteria, with no time-based vesting. The filing says the target value stays at $3.6 million, while the maximum value rises to $5.4 million from $4.5 million under the prior terms. The company also elected John Hart Cole as Co-President and Co-Regional Market Director for Seattle, effective January 1, 2026.
Marcus's 2025 LTI grant, made January 9, 2026, keeps a $3.6 million target value, now fully performance-based.
Maximum value of the 2025 grant rises to $5.4 million, or 150% of the target, from a prior combined maximum of $4.5 million.
The amendment applies only to the 2025 grant and not to later grants or other awards to Marcus.
John Hart Cole was elected Co-President effective January 1, 2026; his only contemplated pay change is a base salary increase, with no amount disclosed.
Diamondback Energy disclosed fourth-quarter 2025 realized prices, derivative results and weighted average share counts in an Item 2.02 filing. The filing does not include revenue, net income, earnings per share or guidance, so shareholders cannot assess overall profitability from it.
Average unhedged realized oil price was $58.00 per barrel; hedged oil price was $57.07 per barrel.
Average unhedged natural gas price was $0.03 per Mcf and hedged price was $1.03 per Mcf; NGL price was $13.51 per barrel.
Expected total gain on derivative instruments was $192 million, including a $73 million net cash gain on settlements.
Basic and diluted weighted average shares outstanding were 285,789 thousand for the quarter.
Flanigan's Enterprises announced a broad leadership reshuffle, with James G. Flanigan II stepping down as President and Chairman, and Jeffrey D. Kastner stepping down as CFO to become Chairman and Chief Legal Officer. Allison Govoni becomes CFO and Peter Bruce becomes COO, both internal promotions, which shareholders may view as a significant change in top management.
James G. Flanigan II resigned as President and Chairman effective January 8, 2026, and remains CEO and a Board member
Jeffrey D. Kastner resigned as CFO effective January 8, 2026, and was named Chief Legal Officer and Chairman of the Board
Christopher O'Neil was named President effective January 8, 2026, with an annual base salary of $464,000
Allison Govoni named CFO effective January 8, 2026, at $222,000 annual base salary; Peter Bruce named COO at $272,000
Sarepta gave preliminary, unaudited fourth-quarter and full-year 2025 results at the J.P. Morgan Healthcare Conference, reporting $369.6 million in fourth-quarter net product revenue and $1.86 billion for the year. The company reconfirmed a yearly ELEVIDYS sales floor of $500.0 million but said it will not provide more detailed 2026 guidance until it evaluates its initiatives. Final results are due in late February 2026 and may differ materially from these figures.
Full-year 2025 total net product revenue of $1.86 billion; fourth quarter $369.6 million
ELEVIDYS fourth-quarter net product revenue of $110.4 million, affected by a severe flu season and rescheduling of 6 patient infusions into 2026
PMO net product revenue of $259.2 million in the fourth quarter and $965.6 million for the full year
Year-end 2025 cash, cash equivalents, restricted cash and investments of approximately $953.8 million; final results expected in late February 2026
On January 12, 2026, Bruker said during a J.P. Morgan Healthcare Conference presentation that preliminary fourth-quarter 2025 revenue is expected to be between $965 million and $970 million. It also outlined a preliminary 2026 outlook calling for flat to low-single-digit organic revenue growth, organic operating margin expansion of 250 to 300 basis points, and double-digit non-GAAP earnings per share growth, each compared with 2025. The fourth-quarter and full-year figures are unaudited and not yet finalized, and final results may differ materially.
Preliminary Q4 2025 revenue expected between $965 million and $970 million
Fourth-quarter 2025 Bruker Scientific Instruments book-to-bill ratio above 1.0
2026 outlook: organic revenue growth flat to up low-single digits versus 2025
2026 outlook: non-GAAP organic operating margin to expand 250 to 300 basis points and non-GAAP EPS to grow in double digits
PTC Therapeutics said preliminary, unaudited 2025 total product and royalty revenue was about $823.4 million, which it describes as exceeding its guidance. The company also guided to 2026 total product revenue of $700 million to $800 million, excluding Evrysdi royalty and collaboration revenue, and to GAAP R&D and SG&A expense of $775 million to $815 million. Final 2025 results remain subject to the year-end audit.
Unaudited 2025 total product and royalty revenue of about $823.4 million; unaudited total product revenue of about $587.8 million
Sephience unaudited Q4 2025 net revenue of about $92.5 million, including $81.6 million in the US and $10.9 million ex-US
2026 guidance: total product revenue of $700 million to $800 million, excluding Evrysdi royalty and collaboration revenue
2026 GAAP R&D and SG&A expense guidance of $775 million to $815 million, or $680 million to $720 million excluding about $95 million of non-cash stock-based compensation
Bristol-Myers Squibb furnished an investor presentation from its 44th Annual J.P. Morgan Healthcare Conference, posted to its website on January 12, 2026. The deck covers Growth Portfolio sales, pipeline timelines, and capital returns, but it reports no new quarterly results or guidance changes.
Growth Portfolio sales rose 17% for the nine months ended 9/30/25 versus the same period in 2024
About $14.5 billion in dividends and about $8 billion in share repurchases over the past three years, per the presentation
Company cites 94 consecutive years of dividend payments; latest dividend declared 12/10/2025 and payable 2/2/2026
Danaher estimated that fourth-quarter 2025 revenue rose in the mid-single digit percent range year over year, with non-GAAP core revenue growth toward the high end of its low-single digit guidance. It also expects full-year 2025 non-GAAP adjusted diluted EPS toward the high end of its $7.70 to $7.80 guidance range, which suggests results came in at or above the company's prior outlook. These figures are preliminary estimates ahead of the January 28, 2026 earnings call.
Q4 2025 estimated revenue growth: mid-single digit percent range year over year
Q4 2025 non-GAAP core revenue growth expected toward the high end of low-single digit guidance
FY 2025 non-GAAP adjusted diluted EPS expected toward the high end of the $7.70 to $7.80 range
CEO Rainer M. Blair to comment at J.P. Morgan Healthcare Conference on January 13, 2026; earnings call January 28, 2026
Concentra published a presentation for the J.P. Morgan Healthcare Conference, to be given January 14, 2026, with preliminary, unaudited Q4 2025 operational metrics. The filing shows early visits-per-day growth but no revenue, profit or earnings per share figures for the quarter, which the company says will come in late January.
Early look shows Q4 2025 visits per day up year over year at +3.4%, +9.1%, +2.3% and +9.4% across total company (excluding Nova), workers' compensation and employer services.
Concentra repurchased about 1.1 million shares in Q4 2025.
Late January: Q4 and FY 2025 flash results and 2026 guidance; regularly scheduled Q4 earnings call in late February.
Presentation lists FY 2025 guidance of $2.145 billion to $2.160 billion in revenue and $425 million to $430 million in Adjusted EBITDA.
Jazz Pharmaceuticals said in a January 12, 2026 filing that it expects to meet its previously announced total revenue guidance range for the year ended December 31, 2025. The company will present the update at the J.P. Morgan Healthcare Conference on January 13, 2026, and says the 2025 results have not been finalized and actual results may differ.
Expects to meet the 2025 total revenue guidance range provided on November 5, 2025
Presentation slides show Xywav and Epidiolex each with $1B+ in 2025 sales, and Modeyso with nearly $50 million in 2025 revenue
Figures are unaudited; the company states 2025 financial results have not been finalized and actual results may differ
Update to be presented January 13, 2026 at the J.P. Morgan Healthcare Conference in San Francisco
Zimmer Biomet said Mark Bezjak, a named executive officer in its 2025 proxy statement, informed the company on January 8, 2026 that he will resign his employment and all officer positions effective January 16, 2026, to pursue another business opportunity. The filing notes he already ceased to be an executive officer on July 1, 2025, so the change is largely a formal exit. The filing does not name a successor.
Mark Bezjak notified the company on January 8, 2026 of his resignation.
Resignation takes effect January 16, 2026, covering his employment and all officer roles at the company and its affiliates.
Bezjak stopped being an executive officer on July 1, 2025, as previously reported.
The filing reports no financial results; its only exhibit is the Inline XBRL cover page file.
Osprey Funds, LLC, the sponsor of Osprey Bitcoin Trust, and Delaware Trust Company signed an amendment on January 9, 2026 to the trust agreement. The change moves the cutoff for cash purchase and redemption orders from 6:00 p.m. to 5:30 p.m. Eastern Time on the business day before the trade date. The filing describes this as an administrative update to order timing, and it does not mention any change to fees, assets or share economics.
Amendment dated January 9, 2026, between Osprey Funds, LLC and Delaware Trust Company
Cash purchase and redemption order cutoff moved from 6:00 p.m. to 5:30 p.m. Eastern Time on the prior business day
Full amendment filed as Exhibit 1.01 to the 8-K; report signed January 12, 2026 by CEO Gregory D. King
MACOM Technology Solutions appointed Bryan Ingram as an independent director effective January 12, 2026, to serve until the 2026 annual meeting. Ingram previously led Broadcom's Wireless Semiconductor Division and served as chief operating officer at Avago Technologies, and the company said he has managed semiconductor businesses with more than $4 billion in revenue. The filing is a board appointment with no financial results or guidance included.
Bryan Ingram appointed to the board effective January 12, 2026, to hold office until the 2026 annual meeting of stockholders
Board determined Ingram is independent under Nasdaq listing rules and SEC rules
Ingram previously served as SVP and General Manager of Broadcom's Wireless Semiconductor Division (November 2015 to October 2019) and as COO of Avago Technologies (April 2013 to October 2015)
Ingram will receive compensation under the company's non-employee director program and has entered into the standard indemnification agreement
Amphenol completed its acquisition of CommScope's Connectivity and Cable Solutions (CCS) business on January 9, 2026, for approximately $10.5 billion in cash, subject to customary post-closing adjustments. Amphenol expects the business to generate approximately $4.1 billion in full-year 2026 sales and to add approximately $0.15 to 2026 diluted earnings per share, excluding acquisition-related expenses. Financial statements and pro forma information for the business will be filed later by amendment.
Acquisition closed January 9, 2026, for approximately $10.5 billion in cash, subject to customary post-closing adjustments
Expected full-year 2026 sales for the CCS business of approximately $4.1 billion
Expected accretion of approximately $0.15 to 2026 diluted EPS, excluding acquisition-related expenses
CCS business will join the Communications Solutions Segment, with approximately 20,000 employees
Allegiant agreed on January 11, 2026 to merge with Sun Country Airlines, with Sun Country becoming a wholly owned subsidiary. Sun Country holders would receive $4.10 in cash and 0.1557 Allegiant shares per share, and the companies say the deal values Sun Country at about $1.5 billion including $0.4 billion of net debt. The deal requires stockholder, regulatory and other approvals and is expected to close in the second half of 2026, with Allegiant shareholders owning about 67% of the combined company.
Sun Country holders would receive $4.10 in cash plus 0.1557 Allegiant shares per share, an implied $18.89 per share, a 19.8% premium to the $15.77 closing price on January 9, 2026.
Allegiant shareholders would own about 67% of the combined company and Sun Country shareholders about 33%, on a fully diluted basis.
Allegiant expects $140 million in annual synergies within three years of closing and says the deal should be accretive to earnings per share one year after closing.
Termination fees range from $30 million to $52.23 million depending on the circumstances, and the agreement can be terminated if the merger is not completed by January 11, 2027.
ADMA Biologics preliminarily estimated unaudited full-year 2025 total revenue of approximately $510-$511 million, which the company says meets or exceeds its prior guidance. It raised its fiscal 2026 revenue and Adjusted EBITDA guidance, and the figures remain subject to audit and change.
Preliminary unaudited FY 2025 total revenue of approximately $510-$511 million, which the company says meets or exceeds prior guidance
FY 2026 revenue guidance raised to approximately $635 million from $630 million previously
FY 2026 Adjusted EBITDA guidance raised to approximately $360 million from $355 million; FY 2026 Adjusted Net Income guidance reiterated at approximately $255 million
Year-end 2025 cash of approximately $88 million, including an unaudited estimate of approximately $40 million operating cash flow in Q4 2025
Harmony Biosciences said preliminary unaudited WAKIX net product revenue was about $868 million for 2025, up from $714.7 million in 2024, and about $243 million for the fourth quarter, up from $201.3 million a year earlier. It also issued 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion and said it is phasing out its ZYN002 Fragile X program. The figures are unaudited and may change after year-end closing and auditor review.
Preliminary 2025 WAKIX net product revenue of about $868 million, versus $714.7 million in 2024 (about 21% growth)
Q4 2025 preliminary net product revenue of about $243 million, versus $201.3 million in Q4 2024
2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion for the year ending December 31, 2026
ZYN002 Fragile X program being phased out after review of RECONNECT study data; 22q deletion indication no longer pursued
Progyny said on January 12, 2026 that its fourth-quarter 2025 revenue, net income and Adjusted EBITDA are now expected to be slightly above the ranges it gave in November 2025. The company said this excludes any non-cash impacts to net income tied to the previously announced departure of president Michael Sturmer, and that member engagement paced favorably during the quarter. Shareholders get an upward revision to recent guidance, though the filing does not give specific dollar figures.
Fourth-quarter 2025 revenue, net income and Adjusted EBITDA are expected to be slightly above the November 2025 guidance ranges.
The outlook excludes any non-cash impacts to net income from the departure of president Michael Sturmer.
CEO Pete Anevski cited member engagement that paced favorably versus the November guidance.
Management will discuss the updated expectations at the JP Morgan Healthcare Conference on Tuesday, January 13, 2026, at 10:30 a.m. Eastern Time.
Vir Biotechnology said it had approximately $781 million in cash, cash equivalents and investments as of December 31, 2025, an unaudited figure, and that this balance is expected to fund operations into the fourth quarter of 2027, which it links to the Norgine licensing agreement and continued financial discipline. It also released updated Phase 2 SOLSTICE data for its chronic hepatitis delta combination therapy, with 88% of participants evaluated through Week 96 reaching undetectable hepatitis delta virus RNA versus 46% on the antibody alone. The filing contains no full-year revenue or profit figures, which the company expects to report in late February 2026.
Preliminary, unaudited cash, cash equivalents and investments of approximately $781 million as of December 31, 2025; full fourth-quarter and 2025 results expected in late February 2026.
Cash runway extended into the fourth quarter of 2027, tied by the company to the Norgine license for chronic hepatitis delta in Europe, Australia and New Zealand.
SOLSTICE Phase 2: undetectable HDV RNA at Week 96 in 88% (21/24) of combination participants versus 46% (11/24) on tobevibart alone.
Company to present at the J.P. Morgan Healthcare Conference on January 14, 2026, at 3:45 p.m. PT.
BioLife Solutions reported preliminary, unaudited revenue from continuing operations of $96.2 million for 2025, up 29% from 2024, and $24.8 million for the fourth quarter, up 20%. The full-year figure exceeded the top of the guidance range raised in November 2025 ($95.0 million to $96.0 million, adjusted for the evo sale). The company said final results may differ and will provide 2026 guidance with its complete 2025 results in February.
Full-year 2025 revenue from continuing operations: $96.2 million, up from $74.6 million in 2024
Fourth-quarter 2025 revenue: $24.8 million, up from $20.7 million a year earlier
Full-year revenue exceeded the top of the raised guidance range of $95.0 million to $96.0 million
About $1.3 million in biopreservation media revenue was accelerated into the third quarter of 2025 at a customer's request, so it is not in fourth-quarter revenue
TransMedics entered a lease on January 8, 2026 for about 498,286 square feet at 188 Assembly Park Drive in Somerville, Massachusetts, to serve as its new headquarters beginning on or before January 1, 2028, replacing its Andover site. The filing also discloses initial annual base rent of about $23.9 million, an $18 million letter of credit security deposit, and the purchase of two adjacent parcels for $15.0 million each.
Lease covers about 498,286 square feet; base rent initially about $23.9 million per year, rising 2% annually
Lease initial term is 192 months from the Rent Commencement Date, with two ten-year extension options
Security deposit delivered as a letter of credit of about $18 million
On January 8, 2026, the company bought two adjacent Somerville parcels for $15.0 million each, plus related costs
Alkermes furnished a corporate presentation for the J.P. Morgan Healthcare Conference that includes preliminary, unaudited estimated total revenues for 2025. The filing says these figures may change after the company completes its year-end financial statement review, and it gives no prior-year comparison or profit figures.
Presentation states the commercial business generated total revenues above $1.45 billion in 2025.
Revenue figures are preliminary and unaudited and subject to change after the year-end review.
Presentation was made available January 12, 2026, for a J.P. Morgan Healthcare Conference presentation on January 13, 2026.
The planned Avadel acquisition is expected to close in Q1 2026.
Krystal Biotech disclosed preliminary, unaudited 2025 results ahead of its J.P. Morgan Healthcare Conference presentation on January 12, 2026, including VYJUVEK net product revenue and cash of about $955 million as of December 31, 2025. It also gave 2026 combined non-GAAP R&D and SG&A expense guidance of $175 million to $195 million. The company said its audit is ongoing and the figures could change, with full 2025 results due in February 2026.
Preliminary Q4 2025 VYJUVEK net product revenue of $106 million to $107 million; full year 2025 of $388 million to $389 million
Cash, cash equivalents and investments of approximately $955 million as of December 31, 2025
2026 combined non-GAAP R&D and SG&A expense guidance of $175 million to $195 million, excluding stock-based compensation
Figures are unaudited and subject to change; full 2025 results to be reported in February 2026
Pegasystems committed on January 7, 2026 to organizational changes, mainly in its Consulting organization, including some role eliminations, to align roles and capacity with an AI-first delivery model. The company expects a charge of approximately $13 million in the fourth quarter of 2025, mostly for cash severance and related benefits.
Changes committed on January 7, 2026, primarily affecting the Consulting organization
Expected charge of approximately $13 million in Q4 2025, mainly cash severance and benefits
Affected employees are being notified; communications expected to be substantially complete in Q1 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.